東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Investigation of VISTA as a Cancer I...

Mehta, Nishant K.

FindBook

Google Book

Amazon

博客來

Investigation of VISTA as a Cancer Immune Checkpoint Via Structural Analysis and Therapeutic Antibody Development.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Investigation of VISTA as a Cancer Immune Checkpoint Via Structural Analysis and Therapeutic Antibody Development./
作者:	Mehta, Nishant K.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2020,
面頁冊數:	198 p.
附註:	Source: Dissertations Abstracts International, Volume: 82-02, Section: B.
Contained By:	Dissertations Abstracts International82-02B.
標題:	Pharmaceutical sciences. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28103996
ISBN:	9798662511422

Investigation of VISTA as a Cancer Immune Checkpoint Via Structural Analysis and Therapeutic Antibody Development.
Mehta, Nishant K.

Investigation of VISTA as a Cancer Immune Checkpoint Via Structural Analysis and Therapeutic Antibody Development. - Ann Arbor : ProQuest Dissertations & Theses, 2020 - 198 p.

Source: Dissertations Abstracts International, Volume: 82-02, Section: B.

Thesis (Ph.D.)--Stanford University, 2020.

This item must not be sold to any third party vendors.

Immunotherapy has shifted the landscape of cancer treatment with the advent of checkpoint inhibitors, which have become the standard of care for multiple types of cancer. Despite the remarkable success of anti-PD1 and anti-CTLA-4, patient response rates to checkpoint blockade are often only 20-30%, necessitating the need for new therapeutic targets. V-domain Ig Suppressor of T cell activation (VISTA) is an orthogonal checkpoint molecule that dampens the interaction between antigen-presenting cells and T cells to prevent effective anti-tumor responses. In this thesis, I present multiple projects related to the characterization of VISTA as a therapeutic target. First, I report the high-resolution crystal structure of the VISTA extracellular-domain and elucidate an important functional epitope of a clinical VISTA antibody (Chapter 2). I used a genetic and enzymatic de-glycoyslation approach to facilitate crystallization and utilized a display-based sorting strategy to isolate hotspot contact residues. Second, I detail the engineering and characterization of a unique, high affinity, species cross-reactive antibody against VISTA (Chapter 4). Using a combination of immune cell assays, epitope mapping strategies, and syngeneic mouse models, I demonstrate the efficacy of this antibody as a VISTA inhibitor. These efforts highlight a promising candidate for therapeutic development and provide a blueprint for future drug discovery campaigns against this promising new checkpoint target.

ISBN: 9798662511422Subjects--Topical Terms:

3173021
Pharmaceutical sciences.
Subjects--Index Terms:

Cancer therapeutics

Investigation of VISTA as a Cancer Immune Checkpoint Via Structural Analysis and Therapeutic Antibody Development.
LDR:02685nmm a2200349 4500 001 2278414
005 20210628075021.5
008 220723s2020 ||||||||||||||||| ||eng d
020 $a 9798662511422
035 $a (MiAaPQ)AAI28103996
035 $a (MiAaPQ)STANFORDmp666bt0191
035 $a AAI28103996
040 $a MiAaPQ $c MiAaPQ
100 1 $a Mehta, Nishant K. $3 3556789
245 1 0 $a Investigation of VISTA as a Cancer Immune Checkpoint Via Structural Analysis and Therapeutic Antibody Development.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2020
300 $a 198 p.
500 $a Source: Dissertations Abstracts International, Volume: 82-02, Section: B.
500 $a Advisor: Cochran, Jennifer;Huang, Possu;Levy, Ronald;Sage, Julien.
502 $a Thesis (Ph.D.)--Stanford University, 2020.
506 $a This item must not be sold to any third party vendors.
520 $a Immunotherapy has shifted the landscape of cancer treatment with the advent of checkpoint inhibitors, which have become the standard of care for multiple types of cancer. Despite the remarkable success of anti-PD1 and anti-CTLA-4, patient response rates to checkpoint blockade are often only 20-30%, necessitating the need for new therapeutic targets. V-domain Ig Suppressor of T cell activation (VISTA) is an orthogonal checkpoint molecule that dampens the interaction between antigen-presenting cells and T cells to prevent effective anti-tumor responses. In this thesis, I present multiple projects related to the characterization of VISTA as a therapeutic target. First, I report the high-resolution crystal structure of the VISTA extracellular-domain and elucidate an important functional epitope of a clinical VISTA antibody (Chapter 2). I used a genetic and enzymatic de-glycoyslation approach to facilitate crystallization and utilized a display-based sorting strategy to isolate hotspot contact residues. Second, I detail the engineering and characterization of a unique, high affinity, species cross-reactive antibody against VISTA (Chapter 4). Using a combination of immune cell assays, epitope mapping strategies, and syngeneic mouse models, I demonstrate the efficacy of this antibody as a VISTA inhibitor. These efforts highlight a promising candidate for therapeutic development and provide a blueprint for future drug discovery campaigns against this promising new checkpoint target.
590 $a School code: 0212.
650 4 $a Pharmaceutical sciences. $3 3173021
650 4 $a Bioengineering. $3 657580
650 4 $a Immunology. $3 611031
653 $a Cancer therapeutics
653 $a Drug discovery
690 $a 0202
690 $a 0982
690 $a 0572
710 2 $a Stanford University. $3 754827
773 0 $t Dissertations Abstracts International $g 82-02B.
790 $a 0212
791 $a Ph.D.
792 $a 2020
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28103996